KR102132604B1 - 비형 간염 표면 항원에 대한 항체 및 그의 용도 - Google Patents

비형 간염 표면 항원에 대한 항체 및 그의 용도 Download PDF

Info

Publication number
KR102132604B1
KR102132604B1 KR1020187013043A KR20187013043A KR102132604B1 KR 102132604 B1 KR102132604 B1 KR 102132604B1 KR 1020187013043 A KR1020187013043 A KR 1020187013043A KR 20187013043 A KR20187013043 A KR 20187013043A KR 102132604 B1 KR102132604 B1 KR 102132604B1
Authority
KR
South Korea
Prior art keywords
seq
antibody
antigen
delete delete
binding fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020187013043A
Other languages
English (en)
Korean (ko)
Other versions
KR20180084045A (ko
Inventor
웬신 루오
빙 주
주안 장
콴 유안
티안잉 장
준 장
닝샤오 시아
Original Assignee
시아먼 유니버시티
양셍탕 컴퍼니 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 시아먼 유니버시티, 양셍탕 컴퍼니 리미티드 filed Critical 시아먼 유니버시티
Publication of KR20180084045A publication Critical patent/KR20180084045A/ko
Application granted granted Critical
Publication of KR102132604B1 publication Critical patent/KR102132604B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—DNA viruses
    • C07K16/082—Hepadnaviridae (F), e.g. hepatitis B virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/61—Fusion polypeptide containing an enzyme fusion for detection (lacZ, luciferase)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
KR1020187013043A 2015-10-09 2016-10-09 비형 간염 표면 항원에 대한 항체 및 그의 용도 Active KR102132604B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201510647977 2015-10-09
CN201510647977.7 2015-10-09
PCT/CN2016/101560 WO2017059813A1 (zh) 2015-10-09 2016-10-09 抗乙肝表面抗原的抗体及其用途

Publications (2)

Publication Number Publication Date
KR20180084045A KR20180084045A (ko) 2018-07-24
KR102132604B1 true KR102132604B1 (ko) 2020-07-13

Family

ID=58487306

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020187013043A Active KR102132604B1 (ko) 2015-10-09 2016-10-09 비형 간염 표면 항원에 대한 항체 및 그의 용도

Country Status (9)

Country Link
US (1) US10689434B2 (cg-RX-API-DMAC10.html)
EP (1) EP3360896B1 (cg-RX-API-DMAC10.html)
JP (2) JP6949012B2 (cg-RX-API-DMAC10.html)
KR (1) KR102132604B1 (cg-RX-API-DMAC10.html)
CN (1) CN106565840B (cg-RX-API-DMAC10.html)
AU (1) AU2016334290B2 (cg-RX-API-DMAC10.html)
CA (1) CA3001231C (cg-RX-API-DMAC10.html)
ES (1) ES3041684T3 (cg-RX-API-DMAC10.html)
WO (1) WO2017059813A1 (cg-RX-API-DMAC10.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2016334290B2 (en) * 2015-10-09 2020-06-18 Xiamen University Antibody to hepatitis B surface antigen and use thereof
CN119490583A (zh) 2018-05-31 2025-02-21 诺华股份有限公司 乙型肝炎抗体
CN118126182A (zh) * 2018-05-31 2024-06-04 第一三共株式会社 抗人tlr7抗体
WO2020130138A1 (ja) * 2018-12-21 2020-06-25 国立大学法人広島大学 抗ｐｒｅＳ１抗体およびその用途
JP7607289B2 (ja) * 2019-05-23 2024-12-27 シァメン・ユニヴァーシティ 新規の抗ｂ型肝炎ウイルス抗体及びその使用
CN111242107B (zh) * 2020-04-26 2021-03-09 北京外号信息技术有限公司 用于设置空间中的虚拟对象的方法和电子设备
CA3184495A1 (en) * 2020-06-08 2021-12-16 F. Hoffmann-La Roche Ag Anti-hbv antibodies and methods of use
WO2024148263A1 (en) * 2023-01-06 2024-07-11 Victorian Infectious Diseases Reference Laboratory Methods and compositions for antibody treatment of hepatitis b infection

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004517636A (ja) 2000-10-02 2004-06-17 コリア リサーチ インスティテュート オブ バイオサイエンス アンド バイオテクノロジー Ｂ型肝炎ウイルスの表面抗原ｓに対するヒト化抗体及びその製造方法
WO2009093263A1 (en) 2008-01-23 2009-07-30 Department Of Biotechnology A humanized high affinity recombinant antibody against hepatitis b surface antigen
JP2013515477A (ja) 2009-12-24 2013-05-09 グリーン クロス コーポレーション Ｂ型肝炎ウイルス表面抗原に特異的に結合するヒト抗体

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1560081A (zh) * 2004-02-17 2005-01-05 大连帝恩生物工程有限公司 用能产生人IgGl重链－κ轻链小鼠作为制备人源化单克隆抗体和应用
CN102786592A (zh) * 2011-05-17 2012-11-21 傅阳心 Hbv特异性抗体
ES2834072T3 (es) 2012-06-11 2021-06-16 Univ Xiamen Polipéptidos y anticuerpos para el tratamiento de la infección por vhb y enfermedades relacionadas
MX363256B (es) * 2012-07-10 2019-03-19 Green Cross Corp Una composición de anticuerpo para la prevención o tratamiento de la infección por el virus mutante de la hepatitis b.
SG10201806025TA (en) * 2014-01-16 2018-08-30 Mario Umberto Francesco Mondelli Neutralizing human monoclonal antibodies against hepatitis b virus surface antigen
AU2016334290B2 (en) * 2015-10-09 2020-06-18 Xiamen University Antibody to hepatitis B surface antigen and use thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004517636A (ja) 2000-10-02 2004-06-17 コリア リサーチ インスティテュート オブ バイオサイエンス アンド バイオテクノロジー Ｂ型肝炎ウイルスの表面抗原ｓに対するヒト化抗体及びその製造方法
WO2009093263A1 (en) 2008-01-23 2009-07-30 Department Of Biotechnology A humanized high affinity recombinant antibody against hepatitis b surface antigen
JP2013515477A (ja) 2009-12-24 2013-05-09 グリーン クロス コーポレーション Ｂ型肝炎ウイルス表面抗原に特異的に結合するヒト抗体

Also Published As

Publication number Publication date
WO2017059813A1 (zh) 2017-04-13
CA3001231C (en) 2022-07-12
US10689434B2 (en) 2020-06-23
CA3001231A1 (en) 2017-04-13
CN106565840B (zh) 2020-09-01
ES3041684T3 (en) 2025-11-13
EP3360896A1 (en) 2018-08-15
AU2016334290B2 (en) 2020-06-18
JP2018533937A (ja) 2018-11-22
JP6949012B2 (ja) 2021-10-13
EP3360896A4 (en) 2019-08-28
EP3360896B1 (en) 2025-07-23
US20190389939A1 (en) 2019-12-26
KR20180084045A (ko) 2018-07-24
AU2016334290A1 (en) 2018-05-10
BR112018007121A2 (pt) 2018-11-06
JP2021063092A (ja) 2021-04-22
CN106565840A (zh) 2017-04-19

Similar Documents

Publication Publication Date Title
CN107151269B (zh) 一种pdl-1抗体、其药物组合物及其用途
JP2026077815A (ja) ヒトｉｌ－４受容体に対する高親和性ヒト抗体
US10689434B2 (en) Antibody against hepatitis B surface antigen and use thereof
JP7332627B2 (ja) 最適化された抗ｔｌ１ａ抗体
JP5818804B2 (ja) ヒトｉｌ−２２ｒａに対するヒト化抗体
KR102561555B1 (ko) Ｂ형 간염 감염 및 관련 질병의 치료를 위한 항체
KR20210121102A (ko) 항-cd79b 항체, 이의 항원-결합 단편, 및 이의 약학적 용도
KR20220167331A (ko) 항-flt3 항체 및 조성물
KR20170110681A (ko) Pcsk9 항체, 및 약제학적 조성물 및 이의 용도
AU2021289612A1 (en) HIV-1 antibodies
CN108178798B (zh) pH工程化的NGF抗体及其医药用途
KR102769097B1 (ko) 항-b형 간염 바이러스 항체 및 이의 용도
CN113549146B (zh) 针对柯萨奇病毒b1型的单克隆抗体及其用途
CN112996540B (zh) 一种c-Met ADC在制备治疗c-Met激酶抑制剂耐药的疾病的药物中的用途
CN115197323B (zh) 一种sn38抗体或其抗原结合片段及其应用
RU2841957C1 (ru) Сконструированные антитела против il-2
KR20260019469A (ko) 만성 D형 간염의 치료를 위한 항-HBsAg 항체
WO2024123897A1 (en) Broadly neutralizing and potent antibodies against hiv
JP2023543826A (ja) 抗ｃｄ３抗体およびその使用
CN121005780A (zh) 靶向hla-g的抗体或其抗原结合片段及其应用

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

PE0801 Dismissal of amendment

St.27 status event code: A-2-2-P10-P12-nap-PE0801

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

P22-X000 Classification modified

St.27 status event code: A-4-4-P10-P22-nap-X000

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 7

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-OTH-PR1001 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 7